FDA Inspection 1330508 — Xellia (Taizhou) Pharmaceuticals Co., Ltd.
The FDA completed an inspection of Xellia (Taizhou) Pharmaceuticals Co., Ltd. on Jul 3, 2026 in Taizhou. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Jul 3, 2026
- Fiscal Year
- 2026
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Taizhou (China)